More than 45 Delegates from the New Zealand Biotechnology Industry
Highlight New Zealand Innovation and Global Connectedness at BIO
2005
BIO 2005 Annual Convention
Over 150 Years of Life Sciences R&D Has Produced a Rapidly Growing
Biotech Industry Addressed to Health and Wellness, Industrial
Biotech, Agriculture, Forestry and More
More than 150 years of life sciences research and technological
innovation, combined with strong global partnerships, and a public-
private collaborative approach to business have given New Zealand
one of the world's fastest growing biotechnology industries. Today
New Zealand biotechnology applications range beyond agriculture to
add medicine, human health, wellness and performance, industrial
biotechnology, forestry, biosecurity, and environmental
applications.
To promote awareness of New Zealand's growing global presence in
biotechnology, the Honorable Pete Hodgson, New Zealand Minister of
Commerce and ex-Minister of Research, Science and Technology will
lead a delegation of 47 companies and organizations to the BIO 2005
conference, taking place in Philadelphia, PA from June 19 - 22.
Through its internationally oriented biotechnology industry and its
presence at BIO 2005, New Zealand is reaching out to partner with
leading U.S. and international research institutions and
universities, companies, and state agencies.
New Zealand Pavilion
The New Zealand Government's economic development agency New Zealand
Trade and Enterprise (NZTE) will host a pavilion in the BIO 2005
Exhibition Hall. The pavilion will showcase a variety of New Zealand
research initiatives and companies in the areas of human medicine,
health and wellness, agricultural biotechnology, industrial
biotechnology and support organizations. The pavilion will include a
meeting area for networking and one-on-one meetings during the
conference. NZTE will co-host with the Australian Pavilion a special
exhibit hall event on Tuesday June 21, 2:00 - 4:00 pm, featuring
fine wines from New Zealand and Australia. The New Zealand Pavilion
is located in Hall C, Stands 749-856.
New Zealand Country Seminar
On Sunday June 19, International Day presenters for New Zealand will
include Minister Hodgson, along with Chris Boalch, Director of
Biotechnology, NZTE; Richard Furneux, Ph.D., CEO of GlycoSyn, an
Industrial Research Ltd company focused on glycobiology; Larry
Ellingson, CEO of Protemix USA, a New Zealand founded
biopharmaceutical company; and Howard Moore, Executive Director of
the recently founded venture firm, BioPacificVentures. Together they
will provide an overview of the New Zealand biotech industry and
business environment, including government initiatives planned to
grow the industry, as well as the New Zealand industry's expanding
international linkages.
The New Zealand Minister of Commerce, Hon. Pete Hodgson, said, "Much
of New Zealand's wealth has been built on a proven ability to add
value to natural resources by applying biological knowledge. Now
unique approaches to biotechnology pioneered in New Zealand are set
to have a major impact on the way we all deal with health and
environmental issues.
"The New Zealand biotech sector has firm backing from the New
Zealand Government which recognises its importance to the economy.
It is working with the New Zealand biotechnology community to
implement a detailed strategy to put in place the necessary
infrastructure to promote success on a global scale."
New Zealand Companies at BIO2005
Representatives of some of New Zealand's leading biotechnology
companies, as well as scientists from cutting edge research programs
at the country's Crown Research Institutes and Universities, will
represent the nation's outstanding capabilities and global research
at BIO2005. Just a few of the New Zealand companies represented at
BIO include:
-- Proacta and Protemix are two companies that illustrate well the
global connectedness of New Zealand biotechnology. Taking advantage
of New Zealand innovation, scientific know-how and low cost of
research, these two companies are among those who have expanded
operations to the United States for access to larger patient
populations and markets. Proacta is developing treatments for cancer
that take advantage of the oxygen-poor environment in tumors.
Protemix is engaged in the development of a novel treatment to
repair heart damage in patients with diabetes, as well as other
therapies for cardiovascular disease, diabetes and other metabolic
conditions.
-- Lactopharma and Ovita are two companies whose research
demonstrates New Zealand's ability to mine leading agricultural
research for new human therapeutic applications. Lactopharma is
developing applications of lactoferrin, a milk-derived protein with
both anti-inflammatory properties and the ability to promote bone
formation and inhibit bone absorption. Ovita's research on muscle
development and twinning in sheep offers opportunities for
development new treatments against muscle wasting and to aid
fertility in humans.
-- Pacific Edge Biotechnology Ltd, a biomedical company with a
strategic focus on "human health and wellness" combines state-of-the-
art molecular biology and micro array technology with world-class
tissue banks and clinical data. These resources, combined with
proprietary analytical software, enable the company to identify
unique gene signatures of disease.
-- IRL - With a focus on creating new technologies, Industrial
Research Ltd (IRL) draws from New Zealand science & technology
platforms to create globally competitive products for customers
worldwide. This focus includes a core emphasis within biotechnology.
For example, one of IRL's key business units, GlycoSyn, is drawing
from world-class expertise in carbohydrate chemistry to collaborate
with Albert Einstein College of Medicine in New York. This
partnership has enabled them to produce novel treatments for cancer
and autoimmune diseases that have led to further clinical
development with companies in the United States and Australia. A
separate spin-out company from Industrial Research, IRL Biopharm,
manufactures many of the potent molecules used as "warheads" in
anticancer antibodies under development by a major US biotech
company.
-- Neuren Pharmaceuticals is a biopharmaceutical company whose
product pipeline is applicable to two of the world's largest and
fastest growing therapeutic markets: neuroprotection and metabolism.
The company has many U.S. and other global collaborations, including
one with Walter Reed Army Institute of Research focused on
neuroprotectant treatments and traumatic brain injury.
For more information on New Zealand and its biotechnology industry,
as well as its participation in BIO 2005, please visit
www.nzte.govt.nz/bio2005.
http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/";>Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/";>Arizona High Tech</a>
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
